# First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

> **NCT07348276** · EARLY_PHASE1 · RECRUITING · sponsor: **Invicro** · enrollment: 24 (estimated)

## Conditions studied

- Progressive Supranuclear Palsy (PSP)
- Healthy Participants

## Interventions

- **DRUG:** [18F]ABBV-964i
- **DRUG:** [18F]ABBV-965i
- **DRUG:** Lead Candidate

## Key facts

- **NCT ID:** NCT07348276
- **Lead sponsor:** Invicro
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348276, "First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07348276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*